metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)
versus placebo plus SoC
	pembrolizumab plus SoC
	KEYNOTE-590 unpublished Future Oncol 2019 Apr;15(10):1057-1066. Lancet. 2021 Aug 28;398(10302):759-771 NCT03189719	RCT	mEC - 1st line (L1)	Pembrolizumab with cisplatin and 5 FU :	placebo with cisplatin and 5 FU :	as first-line treatment in Subjects With Advanced/Metastatic Esophageal squamous Carcinoma or EGJ	373 / 376	NA	conclusif
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-181, 2020 Journal of Clinical Oncology Journal of Clinical Oncology J Clin Oncol 2020 Dec 10;38(35):4138-4148. Pubmed J Clin Oncol 2021 Nov 3;JCO2100601. ESMO Open. 2022 Feb;7(1):100341. NCT02564263	RCT	mEC - 2nd line (L2)	Pembrolizumab	chemotherapy ICC (paclitaxel, docetaxel, or irinotecan)	Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus/ or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) That Have Progressed After First-Line Standard Therapy	314 / 314	NA	inconclusive